Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Equity Average (2016 - 2026)

Insight Molecular Diagnostics' Equity Average history spans 6 years, with the latest figure at -$20.3 million for Q4 2025.

  • On a quarterly basis, Equity Average fell 1486.42% to -$20.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$20.3 million, a 1486.42% decrease, with the full-year FY2025 number at -$21.9 million, down 633.78% from a year prior.
  • Equity Average hit -$20.3 million in Q4 2025 for Insight Molecular Diagnostics, down from -$4.0 million in the prior quarter.
  • Over the last five years, Equity Average for IMDX hit a ceiling of $104.6 million in Q2 2021 and a floor of -$20.3 million in Q4 2025.
  • Historically, Equity Average has averaged $39.9 million across 5 years, with a median of $38.0 million in 2023.
  • Biggest five-year swings in Equity Average: skyrocketed 174.6% in 2021 and later plummeted 1486.42% in 2025.
  • Tracing IMDX's Equity Average over 5 years: stood at $82.3 million in 2021, then crashed by 32.46% to $55.6 million in 2022, then crashed by 49.07% to $28.3 million in 2023, then tumbled by 104.53% to -$1.3 million in 2024, then plummeted by 1486.42% to -$20.3 million in 2025.
  • Business Quant data shows Equity Average for IMDX at -$20.3 million in Q4 2025, -$4.0 million in Q3 2025, and $5.7 million in Q2 2025.